IDO1 and neoplasm: In an immunocompetent B16-OVA melanoma model, while we did not observe tumor acceleration upon IDO1 inhibition (likely because of simultaneous tumor cell and immune cell protection), there was again no improved tumor control (Figure S1E), in line with a previous study.18